Dear Editor, We thank Chen et al. for their thoughtful comments on our study evaluating camrelizumab plus apatinib with or without transarterial chemoembolisation (TACE) as first-line treatment for advanced hepatocellular carcinoma (HCC) [1, 2]. First, we agree that TACE-related heterogeneity is an important consideration.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with R.
Contact R., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack